

Human Genetic Evidence Supporting GDF11 as a Therapeutic Target

Mendelian Randomization Validates GDF11's Role in Brain Health and Neurological Recovery

Executive Summary

Recent human genetic studies using Mendelian randomization (MR) have identified GDF11 as a causal therapeutic target for cognitive performance and brain health. This genetic evidence complements Alevian's preclinical stroke research, providing critical human validation for GDF11's regenerative potential in neurological conditions.

What is Mendelian Randomization?

Mendelian randomization is a powerful epidemiological method that uses genetic variants as natural experiments to determine whether an exposure (such as GDF11 levels) causes an outcome (such as improved brain function). Because genetic variants are randomly assigned at conception, MR studies can establish causal relationships without the confounding that limits traditional observational studies—making them analogous to randomized controlled trials using nature's own randomization.

For drug development, MR provides a cost-effective way to validate therapeutic targets before clinical trials. Drugs targeting genetically validated pathways have been shown to have significantly higher success rates in clinical development.

Key GDF11 Findings from Mendelian Randomization

A comprehensive 2025 study published in *Translational Psychiatry* analyzed over 4,300 druggable genes and identified GDF11 as one of only 13 candidate drug targets with robust causal evidence for improving cognitive performance.

GDF11 Genetic Evidence Summary

Finding	Details
Cognitive Performance	GDF11 identified as causal therapeutic target among 4,300+ druggable genes (colocalization PPH4 > 0.8)
Reaction Time	Causal association: OR = 1.073, 95% CI 1.036–1.112, p = 9.02×10^{-5}
White Matter Integrity	Higher GDF11 associated with lower mean diffusivity (healthier tissue) in multiple brain tracts (p < 0.001)
Brain Connectivity	Protected inferior fronto-occipital and inferior longitudinal fasciculi bilaterally

White Matter Protection

The MR analysis revealed that genetically determined higher GDF11 expression is associated with preserved white matter microstructure across multiple brain regions:

Brain Region	Odds Ratio	P-value
Left Inferior Fronto-Occipital Fasciculus	0.691	2.71×10^{-5}
Right Inferior Fronto-Occipital Fasciculus	0.691	2.75×10^{-5}
Left Inferior Longitudinal Fasciculus	0.745	8.37×10^{-4}
Right Inferior Longitudinal Fasciculus	0.730	3.41×10^{-4}

Note: Lower mean diffusivity values indicate healthier white matter tissue with better structural integrity.

Significance for Stroke Recovery

These human genetic findings directly support Alevian's therapeutic hypothesis and complement our preclinical stroke research:

Human Genetic Validation: MR provides causal evidence in humans that higher GDF11 levels improve cognitive function and protect brain tissue—evidence that animal studies alone cannot provide.

Mechanistic Alignment: The white matter protection observed in MR studies aligns with our preclinical findings showing rGDF11 enhances neovascularization, reduces inflammation, and promotes neurogenesis after stroke.

Cognitive Endpoints: The genetic association with cognitive performance supports including cognitive assessments as meaningful endpoints in stroke recovery clinical trials.

Higher Clinical Success Probability: Drug targets with human genetic support have demonstrated significantly higher success rates in clinical development, reducing the risk of late-stage failures.

Preclinical Validation

Our February 2025 publication in *Stroke* demonstrated that recombinant GDF11 (rGDF11) promotes recovery in a rat permanent ischemia model of stroke. Six independent preclinical studies with blinding and randomization consistently showed:

- Improved sensorimotor function
- Enhanced neovascularization in the cortex
- Increased neurogenesis in the ventricular zone
- Reduced inflammation (dose-dependent CRP reduction)
- Identification of pharmacodynamic biomarkers for clinical translation

Conclusion

The convergence of human genetic evidence from Mendelian randomization with our rigorous preclinical studies establishes a compelling scientific foundation for GDF11 as a therapeutic target for stroke recovery and neurological regeneration. This dual validation—from human genetics and animal models—positions ALE-001 as a scientifically differentiated approach to addressing the massive unmet need in post-stroke recovery.

References

1. Zhang LY, Liu YX, Chu YH, et al. Identification of novel therapeutic targets for cognitive performance and associations with brain health. *Translational Psychiatry*. 2025;15:214. doi:10.1038/s41398-025-03437-w
2. Cohen OS, Sinha M, Wang Y, et al. Recombinant GDF11 Promotes Recovery in a Rat Permanent Ischemia Model of Subacute Stroke. *Stroke*. 2025;56(4):996-1009. doi:10.1161/STROKEAHA.124.049908
3. Acosta JN, Szejko N, Both CP, et al. Mendelian Randomization in Stroke: A Powerful Approach to Causal Inference and Drug Target Validation. *Frontiers in Genetics*. 2021;12:683082. doi:10.3389/fgene.2021.683082
4. Gill D, Georgakis MK, Zuber V, et al. Mendelian Randomization Studies in Stroke: Exploration of Risk Factors and Drug Targets With Human Genetic Data. *Stroke*. 2021;52(9):3068-3077. doi:10.1161/STROKEAHA.120.032617